Targeted Therapy for High-Risk Patients in Sight
The link between chronic inflammation and colorectal cancer is one of the most concerning aspects of long-term IBD. The research team’s analysis of tissue samples from patients with colitis-associated cancer provided a striking visual confirmation of their theory. They found a high concentration of OSM receptors clustered specifically around tumor sites, whereas the surrounding healthy tissue showed no such accumulation. This suggests that the OSM signaling pathway may directly contribute to the environment that allows tumors to form and grow.
While not every IBD patient will develop cancer, the ability to identify those at the highest risk is a major step toward personalized medicine. The complexity of these diseases has long made them difficult to predict, as the progression varies significantly from one individual to the next.
Prof. Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology, and Rheumatology at Charité, emphasizes the importance of this discovery for the future of patient care. "Chronic inflammatory bowel diseases are highly complex and differ from person to person. That’s exactly what makes them so difficult to treat and predict treatment," she says. "Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The transition from laboratory findings to clinical application is already underway. Because the research provided a clear scientific basis for how OSM and IL-22 interact to sustain inflammation, the development of targeted antibodies has become a viable path. Currently, a clinical trial is testing an antibody designed to block the receptors for oncostatin M, specifically targeting the mechanism that Prof. Hegazy and his team identified.
This move toward precision medicine represents a shift in how chronic diseases are managed. Rather than attempting to suppress the entire immune system—which can leave patients vulnerable to infections and other complications—future treatments may focus on disrupting the specific "fuel" that drives an individual patient’s inflammatory "fire." For the young people who comprise the majority of new IBD diagnoses, this research offers the potential for a future where their education and careers are no longer sidelined by the unpredictable and destructive nature of their disease.
The findings from Charité – Universitätsmedizin Berlin mark a significant milestone in the five-year journey to decode the molecular drivers of IBD. By illuminating the destructive partnership between IL-22 and oncostatin M, the team has not only provided a new tool for diagnosis but has also paved the way for a generation of therapies that could offer more effective, targeted, and lasting relief for patients worldwide.
